Tannaz Jamialahmadi, Željko Reiner, Maryam Matbou Riahi, Seyed Ahmad Emami, Zahra Tayarani-Najaran, Sepideh Salehabadi, Prashant Kesharwani, Khalid Al-Rasadi and Amirhossein Sahebkar* Pages 1 - 10 ( 10 )
Background: Statins are primarily used to decrease elevated LDL-cholesterol and thus prevent atherosclerotic cardiovascular disease. Portal hypertension is one of the most important complications of chronic liver disease. Several studies indicated that statins might be beneficial for portal hypertension as well but there is still no clear answer whether this is true or not.
Methods: A literature search of the major databases was performed to find eligible randomized controlled trials (RCTs) analyzing the effect of statins on portal hypertension from inception to February 5th, 2021. Six RCTs with 442 patients who received statin or statin plus carvedilol were finally included. Meta-analysis was performed using the Comprehensive Meta-Analysis V2 software.
Results: Reduction of portal hypertension after statin treatment was not significant (WMD: -0.494, 95% CI: -1.239, 0.252, p=0.194; I2 :0%). The reduction of portal hypertension was robust in the leave-one-out sensitivity analysis.
Conclusion: Treatment with statins did not decrease significantly portal hypertension.
Statins,portal hypertension,chronic liver disease,Rho-kinase activity,nitric oxide